What does the evidence say about Flaxseed LDL Cholesterol Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Flaxseed LDL Cholesterol Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - Hepatic lipid buildup is a key aspect of metabolic dysfunction-associated steatotic liver disease (MASLD), which is now recognized as a common metabolic disorder strongly associated with increased cardiovascular risk []. [Wei Pin-Hui (2026); evidence level 4] - A Western diet is often marked by higher intake of fat and cholesterol, and long-term adherence to this eating pattern may disturb lipid balance, leading to increased circulating triglycerides (TG) and cholesterol levels, and causing lipid buildup in the liver. [Wei Pin-Hui (2026); evidence level 4] - Studies report increased hepatic SREBP-1c under high-fat feeding, although opposite findings have been observed in some models, especially for SREBP-2 under chronic cholesterol-rich conditions []. [Wei Pin-Hui (2026); evidence level 4] - 1 2 3 4 5 Cardiovascular disease (CVD) remains the leading cause of death worldwide and is closely linked to dyslipidemia and ectopic lipid deposition. [Wei Pin-Hui (2026); evidence level 4] - This study aimed to evaluate the impact of consuming crushed flaxseed on cardiovascular risk in 51 menopausal women. [Lenártová P (2024); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.